Form 4: Jazz Pharmaceuticals Executive Patricia Carr Reports Stock Transactions

Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals, reports the acquisition and disposal of ordinary shares and derivative securities.

Summary

• On February 27, 2025, Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals, engaged in multiple transactions involving the company's ordinary shares.
• Carr exercised non-qualified stock options to acquire 4,500 shares at a price of $113.1 and sold the same amount at $144.4162.
• She also exercised options to acquire 313 shares at $123.36 and sold the same amount at $144.4162.
• Additionally, shares were disposed of to cover tax obligations related to vesting restricted stock units, with 371 shares sold at $142.4271 and 497 shares sold at $142.4308.
• Carr also acquired 2,889 restricted stock units at $0.00.
• On February 28, 2025, Carr sold 773 ordinary shares at $143.295.
• Following these transactions, Carr directly owns 9,485 ordinary shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions seem to be routine exercises of stock options and sales to cover tax obligations. There's no indication of significant concern or overwhelming optimism.

Positives

• The exercise of stock options and vesting of restricted stock units indicate confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations could be interpreted as a need for liquidity, although it is a common practice.

Risks

• Significant stock sales by insiders could negatively impact investor sentiment.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects; however, they don't always indicate a definitive trend.

Comparison to Industry Standards

• Comparing Carr's transactions to those of executives at similar pharmaceutical companies like Amgen (AMGN) or Gilead Sciences (GILD) would provide context on whether these actions are typical for the industry.
• For example, if other executives are also exercising options and selling shares to cover tax obligations, it might suggest a broader trend related to compensation structures in the pharmaceutical sector.
• Benchmarking the vesting schedules of Carr's restricted stock units against industry standards could also reveal whether Jazz Pharmaceuticals' equity incentive plan is competitive.

Stakeholder Impact

• The transactions could have a minor impact on shareholders if they interpret the sales negatively, but overall, the impact is likely to be minimal.

Key Dates